{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:09:22Z","timestamp":1787069362853,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.05.009","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T08:30:08Z","timestamp":1685003408000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-5453","authenticated-orcid":false,"given":"Angela","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-506X","authenticated-orcid":false,"given":"MinJae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-3532","authenticated-orcid":false,"given":"James D.","family":"Finklea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ppul.22767","article-title":"Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men","volume":"49","author":"Sutton","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2023.05.009_bib0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: cystic fibrosis foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2023.05.009_bib0003","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMoa1106126","article-title":"Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis","volume":"366","author":"Chotirmall","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.05.009_bib0004","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"issue":"9","key":"10.1016\/j.jcf.2023.05.009_bib0005","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oxfordjournals.aje.a009172","article-title":"Gender gap in cystic fibrosis mortality","volume":"145","author":"Rosenfeld","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.009_bib0006","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jcf.2021.05.012","article-title":"Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations","volume":"20","author":"Montemayor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.009_bib0007","unstructured":"Cystic Fibrosis Foundation Patient Registry, 2020 Annual Data Report. In. Bethesda, Maryland 2021."},{"issue":"18","key":"10.1016\/j.jcf.2023.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.05.009_bib0009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2023.05.009_bib0010","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2023.05.009_bib0011","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0014","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.jcf.2023.05.009_bib0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2023.05.009_bib0016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.jcf.2023.05.009_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/resp.12702","article-title":"Increasing awareness of sex differences in airway diseases","volume":"21","author":"Raghavan","year":"2016","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00475-2020","article-title":"Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes","volume":"7","author":"Lam","year":"2021","journal-title":"ERJ Open Res"},{"issue":"7","key":"10.1016\/j.jcf.2023.05.009_bib0019","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1513\/AnnalsATS.202008-1064OC","article-title":"A prospective study of the effects of sex hormones on lung function and inflammation in women with cystic fibrosis","volume":"18","author":"Holtrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.jcf.2023.05.009_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/IAI.00422-17","article-title":"17beta-estradiol dysregulates innate immune responses to pseudomonas aeruginosa respiratory infection and is modulated by estrogen receptor antagonism","volume":"85","author":"Abid","year":"2017","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.jcf.2023.05.009_bib0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ppul.22967","article-title":"The cystic fibrosis gender gap: potential roles of estrogen","volume":"49","author":"Sweezey","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2023.05.009_bib0022","first-page":"L844","article-title":"Sex hormones regulate CFTR in developing fetal rat lung epithelial cells","volume":"272","author":"Sweezey","year":"1997","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.jcf.2023.05.009_bib0023","first-page":"G747","article-title":"Progesterone and estradiol inhibit CFTR-mediated ion transport by pancreatic epithelial cells","volume":"271","author":"Sweezey","year":"1996","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1164\/rccm.201001-0053OC","article-title":"17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor","volume":"182","author":"Chotirmall","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.009_bib0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/ers.12.59","article-title":"Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis","volume":"6","author":"Chotirmall","year":"2012","journal-title":"Expert Rev Respir Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.05.009_bib0026","first-page":"4025","article-title":"17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia","volume":"118","author":"Coakley","year":"2008","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100633","article-title":"Estradiol increases mucus synthesis in bronchial epithelial cells","volume":"9","author":"Tam","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jcf.2023.05.009_bib0028","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.healun.2016.06.013","article-title":"Lung transplantation and gender effects on survival of recipients with cystic fibrosis","volume":"35","author":"Raghavan","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.jcf.2023.05.009_bib0029","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/rccm.201909-1845LE","article-title":"Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males","volume":"201","author":"Secunda","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0030","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","article-title":"Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males","volume":"20","author":"Aalbers","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.009_bib0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcf.2022.07.008","article-title":"Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study","volume":"22","author":"Mayer-Hamblett","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:12:06Z","timestamp":1767240726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932300139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S156919932300139X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.009","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}